secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2026-06-09T20:05:20+00:00
Accession:  0001193125-26-263722
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Stockholders approve Amended and Restated 2018 Equity Incentive Plan adding 1.76M new shares plus annual increases
--------------------------------------------------------------------------------

- Plan approved with 11.14M for, 433K against; adds 1,756,257 new shares to reserve plus annual 5% increases from 2027-2036.
- Directors Paul B. Manning and Lawrence Eichenfield re-elected with 11.54M and 11.52M votes for, respectively.
- Advisory vote on executive compensation passed with 11.56M for, 34K against.
- Ratification of KPMG LLP as independent auditor for fiscal year 2026 approved with 14.06M for.
- Plan effective immediately upon stockholder approval on June 5, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312526263722/0001193125-26-263722-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312526263722/d139416d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-263722

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer